Iovance Biotherapeutics Inc

IOVA

$36.97

+79.62% (1 year change)

Avg closing price

Price range

Market Cap

$5.51 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-63 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-1.93

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-19.55x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-63.6 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

148

The number of full time employees.

Revenue & Earnings

Balance Sheet

Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

News

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) $IOVA #Stocks #biopharmaceutical #MedicalStocks #Healthcarenews Buy at $23, Sell at $47 IOVA’s tumour infiltrating lymphocyte (TIL) therapy showed promis...

Live Trading News Live Trading News, 4 months ago